Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1-Reference-Cited by-同舟云学术

Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Published:2012-09 Issue:9 Volume:2 Page:798-811
ISSN:2159-8274
Container-title:Cancer Discovery
language:en
Short-container-title:Cancer Discovery

Author:

Byers Lauren Averett,Wang Jing,Nilsson Monique B.,Fujimoto Junya,Saintigny Pierre,Yordy John,Giri Uma,Peyton Michael,Fan You Hong,Diao Lixia,Masrorpour Fatemeh,Shen Li,Liu Wenbin,Duchemann Boris,Tumula Praveen,Bhardwaj Vikas,Welsh James,Weber Stephanie,Glisson Bonnie S.,Kalhor Neda,Wistuba Ignacio I.,Girard Luc,Lippman Scott M.,Mills Gordon B.,Coombes Kevin R.,Weinstein John N.,Minna John D.,Heymach John V.

Publisher

American Association for Cancer Research (AACR)

Subject

Oncology

Cited by 434 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Challenges and future perspectives for the use of temozolomide in the treatment of SCLC;Cancer Treatment Reviews;2024-09

2. Small cell lung cancer: emerging subtypes, signaling pathways, and therapeutic vulnerabilities;Experimental Hematology & Oncology;2024-08-05

3. GCN2 is a determinant of the response to WEE1 kinase inhibition in small-cell lung cancer;Cell Reports;2024-08

4. DNA damage response signatures are associated with frontline chemotherapy response and routes of tumor evolution in extensive stage small cell lung cancer;2024-07-30

5. Navigating a paradigm shift; food and drug administration approved Tarlatamab-dlle redefining the landscape of small cell lung cancer therapy;International Journal of Scientific Reports;2024-07-25